Reports Q2 revenue $1.1B, consensus $1.07B. “Our innovation-driven strategy delivered robust global growth in the second quarter,” said Jay Mazelsky, President and Chief Executive Officer. “We saw exceptional momentum with IDEXX InVue Dx(TM) placements, exceeding expectations as veterinarians adopted this slide-free technology to streamline workflows and gain faster, more accurate clinical insights. This growth builds on the successful launch of IDEXX Cancer Dx(TM) in North America. Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDXX Earnings this Week: How Will it Perform?
- Idexx Laboratories Hold Rating: Balancing Market Softness with Potential Product Growth
- Idexx Laboratories price target raised to $600 from $580 at Leerink
- IDEXX Laboratories Expands Board with New Director
- Idexx Laboratories price target raised to $540 from $510 at Stifel